El­e­vate­Bio adds an­oth­er $525M to its war chest as it looks to build on next-gen man­u­fac­tur­ing 'base­cam­p'

De­spite im­mense clin­i­cal promise, small cell and gene ther­a­py play­ers have faced a chron­ic man­u­fac­tur­ing bot­tle­neck tied to lim­it­ed cash and spe­cial­ized ex­per­tise. Born from the idea of dis­rupt­ing the man­u­fac­tur­ing busi­ness mod­el in that space, El­e­vate­Bio has scored its biggest fundrais­ing round yet to clear the log­jam.

El­e­vate­Bio closed a mas­sive $525 mil­lion Se­ries C it will use to keep build­ing its next-gen start­up en­gine and one-stop-shop cell and gene ther­a­py man­u­fac­tur­ing “ecosys­tem,” the biotech said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER